免疫性血小板减少症治疗新药研究进展被引量：8

Research advances in new drugs for immune thrombocytopenia

导出

摘要免疫性血小板减少性症(ITP)属于自体免疫性疾病,主要特征以持续性血小板减少及皮肤黏膜出血为主。ITP发病机制复杂且尚未完全清楚,目前临床用药主要分为一线治疗药物和二线治疗药物,由于两者都缺乏特异性并有较多的药物不良反应,因此正在研发的多种生物制剂为治疗ITP带来了新的希望。本文综述了治疗ITP的血小板生成素(TPO)类似物、抗体、共刺激信号阻断剂和细胞因子等多种新型生物制剂及旧药新用的研究进展。 Immune thrombocytopenia （ITP） is an autoimmune disorder characterized by continuously decrease of platelet and the skin mucous membrane bleeding. The pathogenesis of ITP remains enigmatic; The currently used drugs can be divided into first - line and second - line that are not specific and may cause many side effects, However, the emerging of new biodrugs brings new hope for the management of ITP In this review, we summarized the research advances of TPO analogues; antibodies, blocking agents of co - stimulatory signals, cytokines and new indications of already - approved drugs.

作者赵新民彭晓赟尹志芳刘石泉龚震 ZHAO Xin-min;PENG Xiao-yun;YIN Zhi-fang;LIU Shi-quan;GONG Zhen(Department of Bioengineering,School of Materials and Chemical Engineering,Hunan City University,Yiyang 413000,Hunan Province,China;Department of Hematology,Yiyang Central Hospival,Yiyang 413000,Hunan Province,China)

机构地区湖南城市学院材料与化学工程学院生物工程系益阳市中心医院血液科

出处《中国临床药理学杂志》 CAS CSCD 北大核心 2018年第22期2657-2660,共4页 The Chinese Journal of Clinical Pharmacology

基金湖南省教育厅资助科研基金资助项目(07A038) 黑茶金花湖南省重点实验室科研基金资助项目(2016TP1022)

关键词血小板减少症免疫性新药单克隆抗体 thrombocytopenia immunity new drug monoclonal antibody

分类号 R973 [医药卫生—药品]

引文网络
相关文献

参考文献2

1儿童原发性免疫性血小板减少症诊疗建议[J].中华儿科杂志,2013,51(5):382-384. 被引量：216
2成人原发免疫性血小板减少症诊断与治疗中国专家共识（2016年版）[J].中华血液学杂志,2016,37(2):89-93. 被引量：418

二级参考文献48

1Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol, 2010, 149: 855-864.
2Rosthcj S, Hedlund-Treutiger I, Rajantie J, et al. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children : A prospective nordic study of an unselected cohort. J Pediatr, 2003, 143:302-307.
3Kiihne T, Buchanan GR, Zimmetlan S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group. J Pediatr, 2003, 143 : 605 -608.
4British Committee for Standards in Hematology General Hematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003. 120:574-596.
5Geddis AE, Balduini CL. Diagnosis of immune thrombocytopenicpurpura in children. Curr Opin Hematol, 2007,14:520-525.
6Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenie purpura of adults and children: report from an international working group. Blood, 2009, 113:2386-2393.
7Blanehette V, Carcao M. Approach to the investigation and management of immune thrombocytopenie purpura in children. Semin Hematol, 2000,37:299-314.
8Beck CE, Nathan PC, Parkin PC, et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr, 2005, 147:521-527.
9Gaines AR. Disseminated intravascular coagulation associated with acutehemoglobinemia or hemoglobinuria following Rh (0) (D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood, 2005,106 : 1532-1537.
10Hedlund-Treutiger I, Henter JI, Elinder G. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol, 2003, 25:139-144.